Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

P Calverley, R Pauwels, J Vestbo, P Jones, N Pride… - The Lancet, 2003 - thelancet.com
Background Inhaled longacting β 2 agonists improve lung function and health status in
symptomatic chronic obstructive pulmonary disease (COPD), whereas inhaled …
被引用次数：1660 相关文章

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial.

P Calverley, R Pauwels, J Vestbo, P Jones… - 0140 …, 2003 - escholar.manchester.ac.uk
BACKGROUND: Inhaled long-acting beta2 agonists improve lung function and health status
in symptomatic chronic obstructive pulmonary disease (COPD), whereas inhaled …

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: A randomised controlled trial

P Calverley, R Pauwels, J Vestbo, P Jones… - The …, 2003 - research.manchester.ac.uk
Background: Inhaled longacting β2 agonists improve lung function and health status in
symptomatic chronic obstructive pulmonary disease (COPD), whereas inhaled …

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial.

P Calverley, R Pauwels, J Vestbo, P Jones… - Lancet (London …, 2003 - europepmc.org
Background Inhaled long-acting beta2 agonists improve lung function and health status in
symptomatic chronic obstructive pulmonary disease (COPD), whereas inhaled …
[PDF] ugent.be

[PDF][PDF] Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

P Calverley, R Pauwels, J Vestbo, P Jones… - THE …, 2003 - backoffice.biblio.ugent.be
Background Inhaled longacting β2 agonists improve lung function and health status in
symptomatic chronic obstructive pulmonary disease (COPD), whereas inhaled …

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

P Calverley, R Pauwels, J Vestbo, P Jones, N Pride… - The Lancet, 2003 - Elsevier
BACKGROUND: Inhaled longacting β2 agonists improve lung function and health status in
symptomatic chronic obstructive pulmonary disease (COPD), whereas inhaled …
[PDF] academia.edu

[PDF][PDF] Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

P Calverley, R Pauwels, J Vestbo, P Jones, N Pride… - THE LANCET, 2003 - academia.edu
Background Inhaled longacting β2 agonists improve lung function and health status in
symptomatic chronic obstructive pulmonary disease (COPD), whereas inhaled …
[PDF] yangmedicine.com

[PDF][PDF] Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

P Calverley, R Pauwels, J Vestbo, P Jones… - THE …, 2003 - yangmedicine.com
Background Inhaled longacting β2 agonists improve lung function and health status in
symptomatic chronic obstructive pulmonary disease (COPD), whereas inhaled …

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

P Calverley, R Pauwels, J Vestbo, P Jones, N Pride… - The Lancet, 2003 - infona.pl
Inhaled longacting β 2 agonists improve lung function and health status in symptomatic
chronic obstructive pulmonary disease (COPD), whereas inhaled corticosteroids reduce the …

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

P Calverley, R Pauwels, J Vestbo, P Jones, N Pride… - The Lancet, 2003 - thelancet.com
Background Inhaled longacting β 2 agonists improve lung function and health status in
symptomatic chronic obstructive pulmonary disease (COPD), whereas inhaled …